SOD1 and amyotrophic lateral sclerosis: To date, only two medicines have been approved by both the US Food and Drug Administration and the European Medicines Agency: Riluzole which prolongs life by only a few months with limited effects on motor deficits [6] and Tofersen, an antisense oligonucleotide only dedicated to the 1%–2% of ALS cases with mutations in SOD1 [7, 8].